214287-74-8Relevant articles and documents
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors
Corbett, Jeffrey W.,Ko, Soo S.,Rodgers, James D.,Gearhart, Lisa A.,Magnus, Nicholas A.,Bacheler, Lee T.,Diamond, Sharon,Jeffrey, Susan,Klabe, Ronald M.,Cordova, Beverly C.,Garber, Sena,Logue, Kelly,Trainor, George L.,Anderson, Paul S.,Erickson-Viitanen, Susan K.
, p. 2019 - 2030 (2007/10/03)
A series of 4-alkenyl and 4-alkynyl-3,4-dihydro-4-(trifluoromethyl)-2- (1H)-quinazolinones were found to be potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type-1 (HIV-1). The 4-alkenyl-3,4-dihydro-4-(triflu
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1
Corbett, Jeffrey W.,Ko, Soo S.,Rodgers, James D.,Jeffrey, Susan,Bacheler, Lee T.,Klabe, Ronald M.,Diamond, Sharon,Lai, Chii-Ming,Rabel, Shelley R.,Saye, Jo Anne,Adams, Stephen P.,Trainor, George L.,Anderson, Paul S.,Erickson-Viitanen, Susan K.
, p. 2893 - 2897 (2007/10/03)
A research program targeted toward the identification of expanded- spectrum nonnucleoside reverse transcriptase inhibitors which possess increased potency toward K103N-containing mutant human immunodeficiency virus (HIV) and which maintain pharmacokinetic
